The Radial Artery Patency Study Investigators Radial Artery and Saphenous Vein Patency more than 5-years Following Coronary Artery Bypass Surgery: Results.

Slides:



Advertisements
Similar presentations
The Radial Artery Patency Study Investigators Radial Artery and Saphenous Vein Patency more than 5-years Following Coronary Artery Bypass Surgery: Results.
Advertisements

ISAR-REACT 2 ESC 2007 M. Seyfarth, A. Kastrati, J. Mehilli, F.-J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, J. Pache, J. Dirschinger, P. B. Berger,
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
ARTS I & II Keith D Dawkins Southampton University Hospital.
J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
Preservation Solutions, Vein Graft Patency, and Outcomes after Coronary Bypass Surgery RE Harskamp, JH Alexander, PJ Schulte, CM Brophy, MJ Mack, ED Peterson,
REVASCULARIZATION Vs MEDICAL THERAPY IN STABLE CAD
The Radial Artery Patency Study Investigators Radial Artery and Saphenous Vein Patency more than 5-years Following Coronary Artery Bypass Surgery: Results.
Coronary Artery Disease in Diabetic Patients, Different from Non-diabetics?
Proximal Protection during Saphenous Vein Graft Intervention using the Proxis™ Embolic Protection System The PROXIMAL Trial Laura Mauri, MD, MSc, FACC,
Configurations of Arterial Grafts : When to use a SV Graft
Enhancement of thrombolysis in AMI is an unmet clinical need Increase the rate of reperfusion without increasing bleeding Reduce the time to complete reperfusion.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
SPIDER Saphenous Vein Graft Protection In a Distal Embolic Protection Randomized Trial Simon R. Dixon MBChB, William W. O’Neill MD William Beaumont Hospital,
How Many Arterial Grafts is Enough?
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
The Impact of Different Treatment Strategies on Cardiac Death and MI Rates in Patients with Type 2 Diabetes and Stable Coronary Disease: A Report from.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.
Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,
David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Are all forms of total arterial revascularisation equal? A comparison of single versus bilateral internal thoracic artery grafting strategies. William.
Radial Artery Grafting When to do it ( when to not do it )
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
M Gaudino. 2 Loop FD et al NEJM 1986 Arterial conduits used for coronary artery bypass grafting - Internal Thoracic Artery - Radial Artery - Right.
Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität Munich, Germany A Polymer-Free Dual Drug-Eluting.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
Total Occlusion Study of Canada (TOSCA-2) Trial
The German Off-Pump Coronary Artery Bypass Grafting in
Single IMA {Single Arterial}
The Evidence For Conduit Choice
Funded by CIHR Grant: MCT NCT
Fig. 1 Clinical model of coronary collateral flow
Saphenous Vein Grafts with Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year.
Comparison of radial artery patency according to proximal anastomosis site: Direct aorta to radial artery anastomosis is superior to radial artery composite.
Circ Cardiovasc Interv
BRIAN BUXTON and philip hayward University of Melbourne, EPWORTH and
Long-term (5- to 20-year) patency of the radial artery for coronary bypass grafting  Paul Achouh, MD, Redha Boutekadjirt, MD, Daniel Toledano, MD, Nadjib.
The long-term impact of diabetes on graft patency after coronary artery bypass grafting surgery: A substudy of the multicenter Radial Artery Patency Study 
Predictors of low cardiac output syndrome after coronary artery bypass
Funded by CIHR Grant: MCT NCT
No-Touch Saphenous Vein Harvesting May Improve Further the Patency of Saphenous Vein Composite Grafts: Early Outcomes and 1-Year Angiographic Results 
for the REGROUP Trial Investigators
Philip A.R. Hayward, FRCS, Brian F. Buxton, FRACS 
Total occlusion and string sign of radial artery versus saphenous vein graft conduits: An updated meta-analysis  Hisato Takagi, MD, PhD, Masafumi Matsui,
Comparison of Radial Artery and Saphenous Vein Graft Stenosis More Than 5 Years After Coronary Artery Bypass Grafting  Manabu Yamasaki, MD, Saswata Deb,
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
To bypass or stent? The changing rules of an advancing game
Preliminary experience with a novel intraoperative fluorescence imaging technique to evaluate the patency of bypass grafts in total arterial revascularization 
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Deep Sternal Wound Infection: Risk Factors and Outcomes
Atlantic Cardiovascular Patient Outcomes Research Team
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

The Radial Artery Patency Study Investigators Radial Artery and Saphenous Vein Patency more than 5-years Following Coronary Artery Bypass Surgery: Results from the Randomized Multicentre Radial Artery Patency Study (RAPS) Funded by CIHR Grant: MCT NCT

The Radial Artery Patency Study Investigators Stephen E. Fremes MD, Saswata Deb MD, Steve K. Singh MD, Randi Feder-Elituv BSc, Andreas Laupacis MD and Eric A. Cohen MD for the Radial Artery Patency Study Investigators April 4, 2001 New Orleans, LA

The Radial Artery Patency Study Investigators Background  Graft patency is a key determinant of long term outcome following coronary artery bypass surgery (CABG)  The internal thoracic artery provides better long-term patency than the saphenous vein for CABG, prompting surgeons to consider additional arterial grafts, including the radial artery

The Radial Artery Patency Study Investigators

Study Question Is the patency of the radial artery superior to the saphenous vein at one year?

The Radial Artery Patency Study Investigators Patients Inclusion Criteria: General  <80 years old  Isolated triple vessel disease  LV Ejection Fraction > 35% Angiographic  >70% stenosis of target RCA and LCX  RCA and LCX graftable and >1.5mm Exclusion Criteria: Exclusion Criteria: Inability to use Radial or Venous Conduit:  Positive Allen’s Test or abnormal ultrasound, vasculitis or Raynaud’s  Bilateral varicose veins and/or stripping Contraindications to Angiography:  Creatinine > 180 μmol/L  Severe PVD  Contrast allergy dye  Geographic inaccessibility

The Radial Artery Patency Study Investigators Study Randomization Study Randomization RCA:RADIALOrSVG LCX:SVGorRADIAL Randomization was performed within patients not between patients LIMA to LAD

The Radial Artery Patency Study Investigators PRIMARY STUDY ENDPOINT: Graft Occlusion at 1 Year Occluded = No Opacification of Distal Vessel (TIMI 0) OR % CI 0.34–0.88 Absolute Difference =5.4% Intention to Treat Analysis NEJM Nov. 25, 2004

The Radial Artery Patency Study Investigators SECONDARY STUDY ENDPOINT: Functional Graft Occlusion at 1 Year TIMI 3 = Patent TIMI 0,1,2 = Occluded Intention to Treat Analysis NEJM Nov. 25, 2004

The Radial Artery Patency Study Investigators Study Question Is the patency of the radial artery superior to the saphenous vein > 5 years following surgery?

The Radial Artery Patency Study Investigators Randomized N= centres N= centres N=501 9 centres 2 centres, N=32 2 centres, N=20 Deaths < 1 yr, N=8 Clinical Follow-Up Enrollment Angiographic Follow-Up Study Patients

The Radial Artery Patency Study Investigators Eligible N=501 N=483 N=369 Protocol Violations, N=16 2 Study Grafts Occluded, N=4 Death 1-5 yrs, N=10 New Med Exclusions, N= 64 Distance to Centre, N=9 LTFU, N=31 N=269 Death 5-6 yrs, N=6 Patient Refusal, N=94 Study Patients Analysis Eligible for Analysis

The Radial Artery Patency Study Investigators Study Patients VariableAngiography, n=269 No Angiography, n=260 Age (yrs) * Age > 70 yrs (%) * Female (%) Urgent (%) CCS Class 3-4 (%)51.3/ /27.7 Diabetes (%) Hypertension (%) Vascular Disease (%) * Creatinine (mol/L)

The Radial Artery Patency Study Investigators Angiographic Results

The Radial Artery Patency Study Investigators PRIMARY STUDY ENDPOINT: Functional Graft Occlusion at 5 Years TIMI 3 = Patent TIMI 0,1,2 = Occluded OR % CI Absolute Difference =6.8% Intention to Treat Analysis, n=234

The Radial Artery Patency Study Investigators SECONDARY STUDY ENDPOINT: Graft Occlusion at 5 Years Occluded = No Opacification of Distal Vessel (TIMI 0) OR % CI Absolute Difference =8.9% Intention to Treat Analysis, n=269

The Radial Artery Patency Study Investigators SECONDARY STUDY ENDPOINT: Graft Stenosis >25% of TIMI 3 Grafts N=164 both grafts patent  Proximal Anastomosis: Radial 9.8% Radial 9.8% SVG 9.8% SVG 9.8%  Graft Body: Radial 6.7% Radial 6.7% SVG 15.2%, p=0.02, OR 0.42, 95% CI 0.18 – 0.90 SVG 15.2%, p=0.02, OR 0.42, 95% CI 0.18 – 0.90  Distal Anastomosis: Radial 6.1% Radial 6.1% SVG 6.7% SVG 6.7%

The Radial Artery Patency Study Investigators SECONDARY STUDY ENDPOINT: Graft Stenosis >25% or Occlusion Occluded = No Opacification of Distal Vessel (TIMI 0) OR % CI Absolute Difference =11.9% Intention to Treat Analysis, n=269

The Radial Artery Patency Study Investigators Clinical Results

The Radial Artery Patency Study Investigators MACE Outcome< 30 days, n= days-1 year, n=561 > 1 year, n=529 Death4 (0.7) 52 (10.0) Cardiac Death 3 (0.5)2 (0.4)26 (4.9) Non-fatal MI55 (9.8)1 (0.2)8 (1.5 Redo CABG002 (0.4) PCI04 (0.7)24 (4.5) Composite Endpoint 59 (10.5)9 (1.2)79 (14.9)

The Radial Artery Patency Study Investigators Survival 5 years years years

The Radial Artery Patency Study Investigators Event-Free Survival 5 years years years

The Radial Artery Patency Study Investigators Limitations  The study design restricted our ability to evaluate the clinical consequences of radial and saphenous grafts.  The patients recruited into the study were young, and generally low risk.

The Radial Artery Patency Study Investigators Conclusions: 5 Year Results  Radial arteries are associated with reduced rates of functional and complete graft occlusion than saphenous veins.  Radial arteries are associated with less graft disease than saphenous veins.

The Radial Artery Patency Study Investigators Clinical Trials of Radial Patency  RAPS, Multi-centre, 561 patients, within-patient randomization, Radial vs SVG to RCA or Cx, NEJM 2004  ISRS (Italy) Single centre, 60 ISRS patients and 60 controls, RA, RITA or SVG to OM1 Circulation 2005; 112(supp I):I  RSVP (UK) Single centre, 142 patients, Radial vs SVG to Cx, Circulation 2008; 117:  VA Trial, Multi-centre, 757 patients, Radial vs SVG to 2 nd largest coronary, JAMA 2011  RAPCO (Australian), Single centre, 619 patients, <70 years, Radial vs free RITA to 2 nd largest coronary >70 years, Radial vs SVG to 2 nd largest coronary 4 manuscripts published concerning “interim” results

The Radial Artery Patency Study Investigators Additional slides  1 year and 5 year results for patients with both studies  Actuarial survival  Mace, including adjudicated outcomes

The Radial Artery Patency Study Investigators PARTICIPATING CENTRES SUNNYBROOK HEALTH SCIENCES CENTRE TORONTO, ON VANCOUVER GENERAL HOSPITAL VANCOUVER, BC Dr. Stephen FremesDr. Guy Fradet Dr. Eric CohenDr. Chris Buller Randi ElituvRebecca Fox/Neetha Hsu LONDON HEALTH SCIENCES CENTRELONDON, ONTORONTO GENERAL HOSPITALTORONTO, ON Dr. Richard NovickDr. Terry Yau Dr. David AlmondDr. Len Schwartz Stephanie FoxKatherine Tsang/Chet Nacario LONDON HEALTH SCIENCES CENTRELONDON, ONUNIVERSITY OF ALBERTA ONEDMONTON, AB Dr. Mary Lee MyersDr. Elliot Gelfand Dr. David AlmondDr. Wayne Tymchak Mary-Ann James/Linda Herris MONTREAL HEART INSTITUTEMONTREAL, QC Dr. Raymond CartierMONTREAL GENERAL HOSPITALMONTREAL, QC Dr. Gilles CoteDr. Jean Francois Morin Carole JesinaDr. Dragatkis Sybil Germain OTTAWA HEART INSTITUTEOTTAWA, ON Dr. Frasier Rubens WINNIPEG HEALTH SCIENCES CENTRE WINNIPEG, MB Dr. Lyall HigginsonDr. Michael Raabe Sharon Finlay/Sarika NaidooDr. John Ducas Angie Munoz/Lisa Montebruno ST. MICHAEL’S HOSPITALTORONTO, ON Dr. David Latter Dr. Randy Watson Mary Keith/Rose Mokbel